Institute of Cancer Research

Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus

Abstract Rare paediatric central nervous system (CNS) tumours comprise a biologically-heterogeneous group of low-incidence diseases that present significant challenges to both therapeutic development and clinical research, limiting the availability of high-quality evidence to gui...

Optimal timing of post-therapeutic [131I]NaI whole-body scintigraphy in predominantly low- and intermediate-risk differentiated thyroid cancer: a secondary analysis of prospectively acquired data and a structured literature review

Abstract Background Post-therapeutic [ 131 I]NaI whole-body scintigraphy (ptWBS) is mandatory after radioiodine therapy (RAIT), but the most suitable acquisition time remains uncertain. We compared image interpretability at early and delayed time points in patients with different...

Priorities for breast cancer risk assessment in UK women under age 50: a survey and discrete choice experiment

BACKGROUND: National guidelines recommend English women between 30 and 49 years with moderate/high risk of breast cancer (BC) be offered screening and prevention interventions. Identification largely relies on family history-based criteria amongst women self-presenting in primary...

Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care

BACKGROUND: The National Institute for Health and Care Excellence (NICE) recommends that women at above-population-level risk of breast cancer (BC) are offered enhanced screening and risk-reducing interventions. Identification of these women largely relies on referral through pri...